A worker at an Amgen research facility in South San Francisco has been hospitalized after a "flash fire" involving hazardous materials.
Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
Novartis prevailed in the latest court battle over jawbone injuries in Zometa patients. The company did properly warn patients about the drug's risks, a New Jersey jury determined after a 13-day trial.
The agenda for the mammalian synthetic biology workshop held at the Massachusetts Institute of Technology last weekend demonstrates that renewed interest in vaccines has opened up new therapeutic targets, which in turn has driven new approaches to manufacturing. And the threats of pandemic flu and bioterrorism have acted as an extra innovation driver.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Novartis is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng's claims that the Swiss drugmaker downplayed the bone drug's risks.
Novartis has grabbed one of two new indications it was shooting for with its rare disease drug Ilaris, one step toward turning the drug into a blockbuster.
Biotech Dendreon, the maker of prostate cancer vaccine Provenge, continues to struggle with earnings even after undertaking a restructuring program which included unloading one of its manufacturing plants.
The H7N9 situation has quieted down since the early days of the outbreak. China switched from daily to weekly updates, and the number of new cases plateaued after live poultry markets were closed. Yet behind the scenes the U.S., China and others are continuing to ready defenses.
A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.